Drug
Petrelintide
Petrelintide: highest development phase Phase 3, developed by Roche, Zealand Pharma. 9 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Roche, Zealand Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Petrelintide NCT07843498 | Phase 3 | Obesity or Overweight |
| Petrelintide NCT07843485 | Phase 3 | Obesity or Overweight |
| Petrelintide NCT07843472 | Phase 3 | Obesity or Overweight |
| Petrelintide NCT06926842 | Phase 2 | Overweight |
| Petrelintide NCT07589686 | Phase 2 | Obesity or Overweight |
| Petrelintide NCT06662539 | Phase 2 | Obesity |
| Petrelintide NCT07076030 | Phase 1 | Renal Impairment |
| Petrelintide NCT07338214 | Phase 1 | Obesity & Overweight |
| Petrelintide NCT07682818 | Phase 1 | Impaired Hepatic Function |
Latest
No recent events.
Follow Petrelintide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.